Navigating the pricing, reimbursement, and market access challenges faced by vaccines and treatments for infectious diseases
International concern about antibiotic resistance is driving the development of new agents.
As your products progress through the pipeline, the challenges are to ensure late-stage development and the pricing and reimbursement strategy are set up for success.
Vaccines are a specialist area with distinct stakeholders and unique clinical and economic considerations.
Accordingly, you must tailor your evidence generation activities and strategic market access for your vaccines and infectious disease treatments. The high cost of antivirals for the treatment of hepatitis C is leading a number of payers to use new measures for budget control. Your products need an innovative approach to real-world evidence generation, pricing, and reimbursement that considers the evolving requirements of payers and regulators.
With strategic insight and advice from our senior leadership team, you will overcome these challenges.
Accelerate market access and competitive advantage for your vaccines and infectious disease treatments
Our pricing and reimbursement expertise has driven competitive advantage for clients across a range of infectious disease indications, such as:
- extraintestinal pathogenic E. coli
- Methicillin-resistant Staphylococcus aureus (MRSA)
- hepatitis C
- human immunodeficiency virus (HIV)
- respiratory syncytial virus (RSV).
We work with clients on cutting-edge projects, multiple advisory boards, and initiatives that are pushing the boundaries with health technology assessment agencies and payers.
We challenge ourselves to anticipate our clients’ needs and tailor our solutions to your specific challenges.Request a call